Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation
| Autor: | Nobuhiko Imahashi, Tomohiro Kinoshita, Shingo Kurahashi, Tatsuya Adachi, Nobuaki Fukushima, Keitaro Tsushita, Tomoki Naoe, Yoshihiro Inamoto, Koichi Miyamura, Isamu Sugiura |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Oncology Melphalan medicine.medical_specialty medicine.medical_treatment Hematopoietic stem cell transplantation Risk Assessment Transplantation Autologous Disease-Free Survival Autologous stem-cell transplantation Bone Marrow Predictive Value of Tests Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Multiple myeloma Aged Analysis of Variance Chemotherapy Hematology business.industry Surrogate endpoint Hematopoietic Stem Cell Transplantation Middle Aged Prognosis medicine.disease Combined Modality Therapy Surgery Thalidomide Treatment Outcome Cytogenetic Analysis Disease Progression Female Multiple Myeloma business medicine.drug |
| Zdroj: | American Journal of Hematology. 84:283-286 |
| ISSN: | 1096-8652 0361-8609 |
| Popis: | High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard therapy for newly diagnosed multiple myeloma. Combinations of recently proposed prognostic factors such as cytogenetics and international scoring system (ISS) may be useful to predict prognosis after ASCT. This study evaluated 60 consecutive patients who underwent ASCT in four institutes. The median age of patients was 57 years old. Cytogenetic analyses of bone marrow at diagnosis detected metaphase abnormalities in 9 of 51 patients and interphase abnormalities in six of 35 patients (17p13 deletion, t(4;14) and t(14;16)). Seventeen patients had ISS stage 3 at diagnosis. Twenty-five patients who had any of these risk factors were defined as high risk. All patients were conditioned with high-dose melphalan. With a median follow-up of 3.4 years, overall survival and event-free survival at 3 years were significantly worse in high-risk patients (48% vs. 97%; P = 0.0005 and 16% vs. 37%; P = 0.038, respectively) despite the higher CR plus VGPR rate among high-risk patients. In addition, survival at 1 year after progression was significantly worse in high-risk patients despite salvage chemotherapy containing thalidomide (32% vs. 100%, P = 0.0001). Combinations of cytogenetics and ISS could readily predict prognosis. Quality of response is a poor surrogate marker for ultimate outcome. High-risk patients may need more effective treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text